XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.2.u1
EARNINGS (LOSS) PER SHARE
 6 Months Ended
Jun. 30, 2024
Earnings Per Share [Abstract]  
EARNINGS (LOSS) PER SHARE EARNINGS (LOSS) PER SHARE
Earnings (loss) per share attributable to Bausch Health Companies Inc. is calculated as follows:
Three Months Ended June 30,Six Months Ended June 30,
(in millions, except per share amounts)2024202320242023
Net income (loss) attributable to Bausch Health Companies Inc.$10 $26 $(54)$(175)
Basic weighted-average common shares outstanding367.9 364.8 367.4 364.1 
Diluted effect of stock options and RSUs2.3 2.3 — — 
Diluted weighted-average common shares outstanding$370.2 $367.1 $367.4 $364.1 
Earnings (loss) per share attributable to Bausch Health Companies Inc.
Basic$0.03 $0.07 $(0.15)$(0.48)
Diluted$0.03 $0.07 $(0.15)$(0.48)
During the six months ended June 30, 2024 and 2023, all potential common shares issuable for stock options and RSUs were excluded from the calculation of diluted loss per share, as the effect of including them would have been anti-dilutive. The dilutive effect of potential common shares issuable for stock options and RSUs on the weighted-average number of common shares outstanding would have been approximately 2,862,000 and 2,859,000 common shares for the six months ended June 30, 2024 and 2023, respectively.
During the three and six months ended June 30, 2024, time-based RSUs, performance-based RSUs and stock options to purchase approximately 15,011,000 and 14,507,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.
During the three and six months ended June 30, 2023, time-based RSUs, performance-based RSUs and stock options to purchase approximately 16,308,000 and 17,613,000 common shares, respectively, were not included in the computation of diluted earnings per share because the effect would have been anti-dilutive under the treasury stock method.
During each of the three and six months ended June 30, 2024 and 2023, an additional 1,208,000 and 90,000 performance-based RSUs, respectively, were not included in the computation of diluted earnings per share as the required performance conditions had not been met.